Profusa Raises 2026 Revenue Guidance to $3 Million Amid Strong Demand

Written by Emily J. Thompson, Senior Investment Analyst

Source: Newsfilter

Updated: Feb 19 2026

0mins

PFSA+0.34%

Should l Buy PFSA?

Source: Newsfilter

Order Growth: Profusa has received multiple purchase orders for its Lumee™ tissue oxygen monitoring system from European distributors and expert physician customers, reflecting strong market demand, leading to an increase in its 2026 revenue guidance to $1.5 million to $3 million, significantly up from the previous range of $500,000 to $2 million.
Clinical Validation: Prominent vascular surgeons presented positive clinical data on Lumee Oxygen for Chronic Limb Threatening Ischemia (CLTI) treatment at the 2026 Leipzig Interventional Course and the 2025 Paris Vascular Insights, further enhancing the product's market credibility.
Regulatory Progress: Profusa anticipates completing its migration to comply with the EU Medical Device Regulation by Q2 2026; while it has already received CE Mark approval, fulfilling these orders remains contingent on meeting the new regulatory requirements to ensure timely delivery post-anticipated regulatory approval in April 2026.
Market Expansion: With the rapid adoption of Lumee Oxygen in Europe, Profusa plans to potentially enter the US market by late 2026, and through its collaboration with the Mayo Clinic, aims to further drive revenue growth in its Healthcare Research business.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy PFSA?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on PFSA

About PFSA

Profusa, Inc. is a commercial stage digital health company. The Company is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Profusa Cancels $15 Million Offering Amid Revenue Reevaluation

Feb 27 2026Newsfilter

Offering Cancellation: Profusa has decided against proceeding with a $15 million public offering, reflecting a reassessment of its projected revenue for 2026, indicating a potential weakening in its short-term liquidity needs in the current market environment.
Focus on Smaller Offering: The company intends to pursue a smaller, more targeted offering to support projected revenue from its LumeeTMOxygen product launch in Europe in Q2 2026 and to accelerate its collaboration with Mayo Clinic, signaling a strategic shift towards addressing specific market demands.
Market Launch Progress: Profusa anticipates launching its products in the European oxygen market in Q2 2026 and plans to enter the U.S. market in late 2026 in collaboration with Mayo Clinic, demonstrating proactive advancements in product development and market outreach.
Operational and Financial Optimization: Chairman and CEO Ben Hwang stated that the decision to cancel the larger offering aligns better with current operational requirements, emphasizing significant progress in strengthening the company's balance sheet and commercial operations, which may lay a foundation for future market performance.

Marriott Vacations Reports Strong Q4, Shares Surge

Feb 26 2026Benzinga

Earnings Beat: Marriott Vacations reported an adjusted EPS of $1.86 for Q4, surpassing market expectations of $1.57, which highlights the company's strong profitability and boosts investor confidence.
Sales Growth: The company's quarterly sales reached $1.323 billion, exceeding the anticipated $1.294 billion, indicating sustained competitiveness in the market and enhancing shareholder value.
Stock Surge: In pre-market trading, Marriott Vacations shares jumped 12.7% to $65.34, reflecting market optimism about the company's future growth potential and likely attracting more investor interest.
Positive Guidance: The company also issued FY26 adjusted EPS guidance above estimates, further solidifying its leadership position in the vacation industry and laying a strong foundation for future growth.